Incyte Corporation vs Suncor Energy Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Suncor Energy Inc. trades at $72.23 (market cap $82.76B). The key difference: Suncor Energy Inc. is far larger — about 3.6× Incyte Corporation's market cap, and Suncor Energy Inc. pays a 2.39% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Suncor Energy Inc. for 57 Days on average.
| INCY | SU | |
|---|---|---|
Market Cap | $22.85B | $82.76B |
Volume | 1,927,029 | 3,832,959 |
Sector | Health | Energy |
52-Week High | $129.93 | $71.87 |
52-Week Low | $83.80 | $38.17 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $18.35B | $89.29B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Suncor Energy (SU) trades at $72.23, up 6.0% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with moving averages supporting further upside, while fundamentals indicate solid profitability with a 14.7% net income margin and attractive valuation at a P/E of 13.46. Recent Q2 2026 earnings beat expectations, and the company is boosting shareholder returns through buybacks and a $0.60 dividend.
The outlook remains positive given robust cash flow, debt reduction, and strategic asset sales, but risks include commodity price volatility and operational disruptions. With 74% analyst buy ratings and institutional confidence, SU offers value in the energy sector, though investors should monitor execution under new leadership and macroeconomic pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →